Category: Compound Notes

A skeptical comparison of the two most-asked-about recovery peptides. Where the literature actually separates them, where the buyer-side hype runs ahead of the data, and how the Wolverine pre-blend earns its place if you stack them.

A clinical-tone timeline of what the published Phase 3 trials actually show across the GLP-class research compound family, week by week, and where the trial endpoints sit relative to when researchers ask the timeline question.

A short history of apigenin, from its identification in chamomile in the 1840s to the modern research that put it back on the longevity-protocol radar, and what the molecular work actually supports for buyers thinking about sleep architecture.

The longevity supplement industry has built itself around NAD+ precursors. The research behind those products is real but smaller in effect than the marketing implies. Here is the sharp version of the comparison, plus where the actual evidence sits.

A history of GHK-Cu from its 1973 isolation in human plasma to the modern skin and connective-tissue research that put it on the protocol radar, and what the published work actually supports.

A patient explainer on Epitalon, where the research came from, what the proposed mechanism is, and how to think about a compound whose evidence base is real but more limited than the longevity-supplement marketing suggests.

A measured clinical summary of MOTS-c, the 16-amino-acid peptide encoded inside mitochondrial DNA, what the published research actually shows in animal models and early human work, and where the compound sits in a longevity-context protocol.

A sharp look at Selank, why this anxiolytic peptide has stayed niche while less-evidenced compounds got mainstream attention, and what the published research actually supports for buyers cutting through the marketing.

An investigative read of Semax, where the cognitive-research claims hold up, where the marketing runs ahead of the data, and what realistic expectations look like for the compound.

A measured clinical summary of Thymosin Alpha-1 (Tα1), the 28-amino-acid immune-modulating peptide with the deepest regulatory and clinical track record in the peptide-research catalogue, and what the published work supports for protocol use.